Researchers are developing new cancer treatments using tiny particles made from chitosan, a natural material, that can deliver medicine directly to colorectal tumors. According to Gram Research analysis of 2026 findings, these nanocomposites improved drug delivery to tumors and reduced side effects in preclinical studies by targeting cancer cells while sparing healthy tissue. The approach combines chemotherapy with other therapies to overcome drug resistance, though human clinical trials are still in early stages.
Scientists are developing a new way to deliver cancer-fighting drugs directly to tumors in the colon using tiny particles made from chitosan, a natural material derived from shellfish shells. According to Gram Research analysis, these nanocomposites can release medicine slowly and precisely where it’s needed, reducing damage to healthy cells. A 2026 review in the International Journal of Pharmaceutics examined how researchers are designing these smart delivery systems with special targeting molecules and combination therapies. Early laboratory and animal studies show these treatments could improve how well drugs work while causing fewer side effects than traditional chemotherapy.
Key Statistics
A 2026 review in the International Journal of Pharmaceutics found that chitosan-based nanocomposites improved drug bioavailability and tumor accumulation while reducing systemic toxicity in preclinical studies of colorectal cancer treatment.
Colorectal cancer accounts for nearly 10% of all cancer deaths globally, causing over 900,000 deaths annually, according to the 2026 research review examining chitosan nanocomposites as a potential solution to drug resistance and poor drug delivery.
Early clinical studies of chitosan-based targeted delivery systems reported favorable safety profiles and improved pharmacokinetic properties, suggesting potential for next-generation colorectal cancer nanomedicine, per the 2026 International Journal of Pharmaceutics review.
Combination approaches integrating chemotherapy with gene therapy or immunotherapy in chitosan nanocomposites showed enhanced efficacy against resistant tumors in preclinical research, addressing a major limitation of single-drug treatments.
The Quick Take
- What they studied: How tiny particles made from chitosan (a natural substance) can be designed to deliver cancer drugs directly to colorectal tumors while minimizing harm to healthy tissue.
- Who participated: This was a review article that analyzed research from multiple preclinical studies (lab and animal tests) and early human trials. No single patient group was studied.
- Key finding: Chitosan-based nanocomposites showed improved drug delivery to tumors, better drug effectiveness, and reduced side effects compared to traditional chemotherapy approaches in preclinical studies.
- What it means for you: This research is still in early stages, but it suggests future colorectal cancer treatments could be more effective and cause fewer side effects. However, these therapies are not yet available for patients outside of clinical trials.
The Research Details
This was a comprehensive review article, meaning researchers examined and summarized findings from many different studies on chitosan-based cancer treatments. They looked at laboratory experiments, animal studies, and early human trials to understand how well these new delivery systems work.
The review focused on chitosan, a natural material made from shellfish shells that has special properties: it can respond to different pH levels (acidity), stick to the colon lining, and break down naturally in the body. Researchers have been combining chitosan with other materials and adding special targeting molecules (like folate) to make it even more effective at finding and attacking cancer cells.
The scientists also examined combination approaches where multiple types of therapy—chemotherapy drugs, gene therapy, and immune therapy—are delivered together in these nanoparticles to overcome cancer resistance.
A review approach is valuable because it synthesizes information from many studies, helping identify patterns and promising directions. This type of analysis is important for understanding where the field is heading and what challenges still need to be solved before these treatments reach patients.
As a review article published in a respected pharmaceutical journal, this work provides a comprehensive overview of current research. However, readers should understand that the actual clinical evidence is still limited—most findings come from laboratory and animal studies. The review identifies both successes and remaining challenges, which is a sign of scientific honesty. Early human trials show promise but are not yet conclusive.
What the Results Show
Research shows that chitosan-based nanocomposites can successfully deliver cancer drugs directly to colorectal tumors while avoiding healthy tissue. The particles work by responding to the acidic environment of the colon and sticking to the tumor area, releasing medicine slowly over time.
Preclinical studies (lab and animal tests) demonstrated that these smart delivery systems improved how much drug actually reaches the tumor—a problem called ‘bioavailability’ that limits traditional chemotherapy. The nanocomposites also reduced the amount of drug circulating throughout the body, which means fewer side effects in healthy organs.
When researchers combined multiple therapies in one nanoparticle—for example, pairing chemotherapy with immune-boosting treatments—they saw better results against resistant cancers that don’t respond to single drugs. Early safety studies in humans showed favorable results and good tolerability, though larger trials are needed.
Scientists discovered that adding special targeting molecules (like folate or hyaluronic acid) to the nanoparticles made them even better at finding cancer cells specifically. Enzyme-triggered systems that activate only in the tumor environment also showed promise. Researchers are also developing ‘smart hydrogels’—gel-like materials that respond to specific signals—to further improve drug release timing and location.
Traditional chemotherapy drugs often don’t reach tumors effectively and damage healthy cells throughout the body. This new approach builds on decades of nanotechnology research but specifically optimizes the delivery system for colorectal cancer. Previous attempts at targeted delivery faced challenges like rapid clearance from the body and poor stability, which chitosan’s natural properties help overcome.
This review examined mostly preclinical research (lab and animal studies), which don’t always translate to human results. Clinical trial data in humans is still very limited. The review identifies ongoing technical challenges: chitosan particles can dissolve too quickly at certain pH levels, and the body sometimes clears them before they reach the tumor. Researchers are working on solutions like coating the particles with PEG (a protective polymer) and creating hybrid materials, but these approaches need more testing.
The Bottom Line
These chitosan-based treatments are not yet available for patient use. Current evidence (moderate confidence from preclinical studies, low confidence from early human data) suggests they could become valuable tools in colorectal cancer treatment. Patients should continue following standard treatment recommendations while staying informed about clinical trials testing these new approaches.
Colorectal cancer patients and their families should be aware of this emerging technology, especially those interested in clinical trial participation. Oncologists and researchers developing new cancer treatments should follow this field closely. People with family histories of colorectal cancer may want to stay informed about prevention advances.
These treatments are likely 5-10 years away from widespread availability. Early-phase clinical trials are underway, but larger safety and effectiveness studies are needed before regulatory approval. Patients should not expect these therapies to be available immediately but may encounter them through clinical trial opportunities in the coming years.
Frequently Asked Questions
What is chitosan and why is it used for cancer treatment?
Chitosan is a natural material derived from shellfish shells that can respond to body chemistry, stick to the colon, and break down safely. These properties make it ideal for delivering cancer drugs directly to tumors while minimizing damage to healthy cells, according to 2026 research.
When will chitosan cancer treatments be available to patients?
These treatments are still in early clinical trials and likely 5-10 years from widespread availability. Patients interested in accessing them sooner can explore clinical trial opportunities through ClinicalTrials.gov or their oncologist.
How do chitosan nanoparticles target cancer cells specifically?
Researchers attach special targeting molecules (like folate) to the nanoparticles that recognize and bind to cancer cells. The particles also respond to the acidic tumor environment, releasing medicine only where it’s needed, reducing side effects.
Are chitosan cancer treatments safe based on current research?
Early human studies show favorable safety profiles, but large-scale clinical trials are still ongoing. Preclinical research demonstrates reduced systemic toxicity compared to traditional chemotherapy, though more human data is needed for definitive conclusions.
Can chitosan treatments work against drug-resistant colorectal cancer?
Preclinical studies show promise when combining chemotherapy with gene therapy or immunotherapy in chitosan nanoparticles. This multi-drug approach addresses drug resistance, though human clinical evidence is still limited and developing.
Want to Apply This Research?
- Users interested in colorectal cancer research could track clinical trial availability by setting reminders to check ClinicalTrials.gov monthly for new chitosan-based nanocomposite studies in their region.
- Set a quarterly reminder to discuss emerging colorectal cancer treatments with your healthcare provider, and bookmark reliable sources (NIH, cancer.gov) to stay informed about new therapeutic options as they develop.
- Create a ‘Cancer Research Updates’ folder in the app to save articles about targeted drug delivery advances, and use the reminder feature to check for new clinical trial openings every 3 months if you or a loved one has colorectal cancer.
This article reviews emerging research on chitosan-based nanocomposites for colorectal cancer. These treatments are not yet approved for patient use and are primarily in preclinical and early clinical development stages. The findings discussed are based on laboratory, animal, and limited human studies. Patients with colorectal cancer should continue following their oncologist’s treatment recommendations and discuss any interest in experimental therapies or clinical trials with their healthcare team. This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.